In 2024, there is an urgent need for policies that will accelerate biosimilar use to achieve lower system-wide health care costs.
Thomas Newcomer, MBA
Advertisement
Articles by Thomas Newcomer, MBA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Breaking News: AstraZeneca, White House Announce Most-Favored-Nation Deal
2
New Report Details Rising Incidence of Invasive Lobular Carcinoma
3
Tramadol and Antidepressants Linked to Increased Seizure Risk in Older Adults
4
FDA Approves Expanded Indication for Risperidone Extended-Release Injectable to Treat Bipolar I Disorder
5
